Tonix Pharmaceuticals Holding Corp. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

SALE OF COMMON STOCK (Details Narrative)

SALE OF COMMON STOCK (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands												3 Months Ended		6 Months Ended	12 Months Ended
	Jul. 31, 2024	Jul. 09, 2024	Jun. 27, 2024	Jun. 12, 2024	Apr. 02, 2024	Mar. 28, 2024	Dec. 20, 2023	Oct. 03, 2023	Aug. 01, 2023	Jul. 27, 2023	Apr. 08, 2020	Mar. 17, 2025	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Sep. 30, 2024	May 22, 2024	Jan. 25, 2024	Jan. 31, 2023
Class of Stock [Line Items]
Common stock, authorized														1,000,000,000	1,000,000,000	160,000,000			1,000,000,000
Repurchase of common stock																$ 13,965
2024 Share Repurchase Program [Member]
Class of Stock [Line Items]
Share repurchase authorized amount																	$ 10,000
2022 Share Repurchase Program [Member]
Class of Stock [Line Items]
Share repurchase authorized amount													$ 12,500
Shares repurchased													786
Repurchase of common stock													$ 12,500
2022 Share Repurchase Program [Member] \| Minimum [Member]
Class of Stock [Line Items]
Price per share													$ 8,800.00
2022 Share Repurchase Program [Member] \| Maximum [Member]
Class of Stock [Line Items]
Price per share													$ 27,552.00
2023 Share Repurchase Program [Member]
Class of Stock [Line Items]
Share repurchase authorized amount																				$ 12,500
Shares repurchased													50
Price per share													$ 22,784.00
Repurchase of common stock													$ 1,100
Pre-Funded Warrants [Member]
Class of Stock [Line Items]
Number of warrants exercised															113,155
Common Warrants [Member]
Class of Stock [Line Items]
Number of shares for common warrants					2,172
Exercise price					$ 1,056.00													$ 1,056.00
Termination date					Apr. 01, 2029
Common Warrants Series A [Member]
Class of Stock [Line Items]
Number of shares for common warrants					2,782
Termination date					Apr. 01, 2029
Common Warrants Series B [Member]
Class of Stock [Line Items]
Number of shares for common warrants					2,782
Termination date					Apr. 01, 2025
Common Warrants Series C [Member]
Class of Stock [Line Items]
Number of shares for common warrants					10,884
Termination date					Apr. 01, 2026
Period of trading days after FDA acceptance of NDA for warrant expiration					10 days
Common Warrants Series D [Member]
Class of Stock [Line Items]
Number of shares for common warrants					10,884
Termination date					Apr. 01, 2029
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued															77,635
Stock offering expenses															$ 7,238	$ 2,800
Shares repurchased																836
Subsequent Event [Member] \| 2024 Share Repurchase Program [Member]
Class of Stock [Line Items]
Shares repurchased												250,000
Repurchase of common stock												$ 3,000
Subsequent Event [Member] \| 2024 Share Repurchase Program [Member] \| Minimum [Member]
Class of Stock [Line Items]
Price per share												$ 9.98
Subsequent Event [Member] \| 2024 Share Repurchase Program [Member] \| Maximum [Member]
Class of Stock [Line Items]
Price per share												$ 14.33
Sales Agreement [Member]
Class of Stock [Line Items]
Number of shares issued						3,365		1,266		791
Net proceeds						$ 3,900		$ 4,000	$ 6,300
Price per share						$ 960.00
Stock offering expenses						$ 500		500	700
Placement agent fees						$ 300		$ 300	$ 500
Offset to proceeds from issuance of warrants															$ 3,000
Sales Agreement [Member] \| Pre-Funded Warrants [Member]
Class of Stock [Line Items]
Number of shares for common warrants						1,219		1,549		1,399
Price per share						$ 959.68		$ 1,599.68		$ 3,199.68
Sales Agreement [Member] \| Common Warrants Series E [Member]
Class of Stock [Line Items]
Number of shares for common warrants						4,584
Exercise price						$ 1,056.00
Warrants term						5 years 6 months
Sales Agreement [Member] \| Common Warrants [Member]
Class of Stock [Line Items]
Number of shares for common warrants										2,188
Price per share								$ 1,600.00		$ 3,200.00
Exercise price										$ 3,200.00
Sales Agreement [Member] \| Common Warrants Series A [Member]
Class of Stock [Line Items]
Number of shares for common warrants								2,813
Exercise price								$ 1,600.00
Warrants term								5 years
Sales Agreement [Member] \| Common Warrants Series B [Member]
Class of Stock [Line Items]
Number of shares for common warrants								2,813
Exercise price								$ 1,600.00
Warrants term								1 year
Sales Agreement [Member] \| Subsequent Event [Member]
Class of Stock [Line Items]
Net proceeds												$ 46,300
Sales Agreement [Member] \| Alliance Global Partners [Member]
Class of Stock [Line Items]
Offering price per agreement	$ 250,000										$ 320,000
Commission to agent	3.00%										3.00%
Number of shares issued														4,200,000		322
Net proceeds														$ 128,400		$ 3,000
Sales Agreement [Member] \| Alliance Global Partners [Member] \| Subsequent Event [Member]
Class of Stock [Line Items]
Number of shares issued												2,300,000
Net proceeds												$ 46,300
Purchase Agreement [Member]
Class of Stock [Line Items]
Number of shares issued			28,339	11,995			7,920
Net proceeds		$ 3,500	$ 3,400	$ 3,400
Price per share			$ 57.00	$ 106.50
Offering expenses		500
Placement Agent Fees		$ 300
Stock offering expenses			$ 600	$ 600			$ 2,300
Placement agent fees			$ 300	$ 300
Proceeds from equity offerings							$ 30,000
Purchase Agreement [Member] \| Pre-Funded Warrants [Member]
Class of Stock [Line Items]
Number of shares for common warrants		37,032	42,282	25,682			8,973
Price per share		$ 56.99	$ 56.99	$ 106.40			$ 1,775.68
Exercise price							$ 0.32
Number of warrants exercised							2,034
Purchase Agreement [Member] \| Common Warrants [Member]
Class of Stock [Line Items]
Price per share							$ 1,776.00
Purchase Agreement [Member] \| Common Warrants Series C [Member]
Class of Stock [Line Items]
Number of shares for common warrants							25,338
Exercise price							$ 1,776.00
Warrants term							2 years
Period of trading days after FDA acceptance of NDA for warrant expiration							10 days
Common stock, authorized for warrant exercise																1,000,000,000
Period of trading days after approval date to become exercisable							10 days
Purchase Agreement [Member] \| Common Warrants Series D [Member]
Class of Stock [Line Items]
Number of shares for common warrants							25,338
Exercise price							$ 2,720.00
Warrants term							5 years
Purchase Agreement [Member] \| Equity Classified Common Warrants D [Member]
Class of Stock [Line Items]
Number of shares for common warrants							15,917
Stock offering expenses							$ 1,400
Purchase Agreement [Member] \| Liability Classified Common Warrants C and D [Member]
Class of Stock [Line Items]
Number of shares for common warrants							9,422
Stock offering expenses							$ 900
Purchase Agreement [Member] \| Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued		33,936
Price per share		$ 57.00